Gaps in naloxone ownership among people who inject drugs during the fentanyl wave of the opioid overdose epidemic in New York City, 2018

References

• Mattson CL, Tanz LJ, Quinn K, Kariisa M, Patel P, Davis NL. Trends and geographic patterns in drug and synthetic opioid overdose deaths – United States, 2013–2019. MMWR Morb Mortal Wkly Rep. 2021;70(6):1172–207.
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Rising numbers of deaths involving fentanyl and fentanyl analogs, including carfentanil, and increased usage and mixing with non-opioids. Health Alert Network 2018; https://emergency.cdc.gov/han/HAN00413.asp.
   Google Scholar
• New York City Department of Health and Mental Hygiene. Presence of fentanyl in cocaine contributing to increase in drug overdose deaths. Health Advisory 2017; https://www1.nyc.gov/assets/doh/downloads/pdf/han/advisory/fentanyl-advisory10.pdf.
   Google Scholar
• Colon-Berezin C, Nolan ML, Blachman-Forshay J, Paone D. Overdose deaths involving fentanyl and fentanyl analogs – New York City, 2000–2017. MMWR Morb Mortal Wkly Rep. 2019;68(2):37–40.
   PubMed Web of Science ®Google Scholar
• Nolan ML, Tuazon E, Paone D. Unintentional Drug Poisoning (Overdose) Deaths in New York City in 2019. New York City: Department of Health and Mental Hygiene; 2020.
   Google Scholar
• Centers for Disease Control and Prevention. Evidence-based strategies for preventing opioid overdose: What’s working in the United States. 2018; http://www.cdc.gov/drugoverdose/pdf/pubs/2018-evidence-based-strategies.pdf. Accessed July 13, 2021.
   Google Scholar
• Smart R, Pardo B, Davis CS. Systematic review of the emerging literature on the effectiveness of naloxone access laws in the United States. Addiction. 2021;116(1):6–17.
   PubMed Web of Science ®Google Scholar
• Cataife G, Dong J, Davis CS. Regional and temporal effects of naloxone access laws on opioid overdose mortality. Subst Abus 2020;17:1–10.
   Google Scholar
• You H, Ha J, Kang C, et al. Regional variation in states’ naloxone accessibility laws in association with opioid overdose death rates-Observational study (STROBE compliant). Medicine. 2020;99(22):e20033.
   PubMed Web of Science ®Google Scholar
• Jones AA, Park JN, Allen ST, et al. Racial differences in overdose training, naloxone possession, and naloxone administration among clients and nonclients of a syringe services program. J Subst Abuse Treat. 2021;129:108412.
   PubMed Web of Science ®Google Scholar
• Kinnard EN, Bluthenthal RN, Kral AH, Wenger LD, Lambdin BH. The naloxone delivery cascade: identifying disparities in access to naloxone among people who inject drugs in Los Angeles and San Francisco, CA. Drug Alcohol Depend. 2021;225:108759.
   PubMed Web of Science ®Google Scholar
• Allen ST, White RH, O'Rourke A, Grieb SM, Kilkenny ME, Sherman SG. Take-home naloxone possession among people who inject drugs in rural West Virginia. Drug Alcohol Depend. 2019;204:107581.
   PubMed Web of Science ®Google Scholar
• Lipira L, Leichtling G, Cook RR, et al. Predictors of having naloxone in urban and rural Oregon findings from NHBS and the OR-HOPE study. Drug Alcohol Depend. 2021;227:108912.
   PubMed Web of Science ®Google Scholar
• Shrestha S, Stopka TJ, Hughto JMW, et al. Prevalence and correlates of non-fatal overdose among people who use drugs: findings from rapid assessments in Massachusetts, 2017–2019. Harm Reduct J. 2021;18(1):93.
   PubMed Web of Science ®Google Scholar
• Buresh M, Gicquelais RE, Astemborski J, Kirk GD, Mehta SH, Genberg BL. Fatal overdose prevention and experience with naloxone: a cross-sectional study from a community-based cohort of people who inject drugs in Baltimore, Maryland. PLoS One. 2020;15(3):e0230127.
   PubMed Web of Science ®Google Scholar
• Dayton L, Gicquelais RE, Tobin K, et al. More than just availability: Who has access and who administers take-home naloxone in Baltimore, MD. PLoS One. 2019;14(11):e0224686.
   PubMed Web of Science ®Google Scholar
• Ong AR, Lee S, Bonar EE. Understanding disparities in access to naloxone among people who inject drugs in Southeast Michigan using respondent driven sampling. Drug Alcohol Depend. 2020;206:107743.
   PubMed Web of Science ®Google Scholar
• Naumann RB, Durrance CP, Ranapurwala SI, et al. Impact of a community-based naloxone distribution program on opioid overdose death rates. Drug Alcohol Depend 2019;2014:107356.
   Google Scholar
• Walley AY, Xuan Z, Hackman HH, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013; 346:f174.
   PubMed Web of Science ®Google Scholar
• Lambdin BH, Bluthenthal RN, Wenger LD, et al. Overdose education and naloxone distribution within syringe service programs – United States, 2019. MMWR Morb Mortal Wkly Rep. 2020;69(33):1117–1121.
   PubMed Web of Science ®Google Scholar
• Dasgupta N, Doe Simkins M, Wheeler E. Opioid Safety and Naloxone Network Buyers Club: Restoring Naloxone. http://localhost/files/qr46r915r2021.
   Google Scholar
• Sherman SG, Morales KB, Park JN, McKenzie M, Marshall BDL, Green TC. Acceptability of implementing community-based drug checking services for people who use drugs in three United States cities: Baltimore, Boston and Providence. Int J Drug Policy. 2019;68:46–53.
   PubMed Web of Science ®Google Scholar
• Baggett TP, Hwang SW, O’Connell JJ, et al. Mortality among homeless adults in Boston: shifts in causes of death over a 15-year period. JAMA Intern Med. 2013;173(3):189–195.
   PubMed Web of Science ®Google Scholar
• van Draanen J, Tsang C, Mitra S, Karamouzian M, Richardson L. Socioeconomic marginalization and opioid-related overdose: a systematic review. Drug Alcohol Depend. 2020;214:108127.
   PubMedGoogle Scholar
• Yamamoto A, Needleman J, Gelberg L, Kominski G, Shoptaw S, Tsugawa Y. Association between homelessness and opioid overdose and opioid-related hospital admissions/emergency department visits. Soc Sci Med. 2019;242:112585.
   PubMed Web of Science ®Google Scholar
• Mital S, Wolff J, Carroll JJ. The relationship between incarceration history and overdose in North America: a scoping review of the evidence. Drug Alcohol Depend. 2020;213:108088.
   PubMed Web of Science ®Google Scholar
• Sugarman OK, Bachhuber MA, Wennerstrom A, Bruno T, Springgate BF. Interventions for incarcerated adults with opioid use disorder in the United States: a systematic review with a focus on social determinants of health. PLoS One. 2020;15(1):e0227968.
   PubMed Web of Science ®Google Scholar
• Lim S, Seligson AL, Parvez FM, et al. Risks of drug-related death, suicide, and homicide during the immediate post-release period among people released from New York City jails, 2001–2005. Am J Epidemiol. 2012;175(6):519–526.
   PubMed Web of Science ®Google Scholar
• Fine DR, Yu L, Triant VA, Baggett TP, Metlay JP. Baseline factors associated with mortality in patients who engaged in buprenorphine treatment for opioid use disorder: a cohort study. J Gen Intern Med. 2020;35(8):2375–2382.
   PubMed Web of Science ®Google Scholar
• Marshall JR, Gassner SF, Anderson CL, Cooper RJ, Lotfipour S, Chakravarthy B. Socioeconomic and geographical disparities in prescription and illicit opioid-related overdose deaths in Orange County, California, from 2010 to 2014. Subst Abus. 2019;40(1):80–86.
   PubMed Web of Science ®Google Scholar
• McKnight C, Des Jarlais DC. Being “hooked up” during a sharp increase in the availability of illicitly manufactured fentanyl: adaptations of drug using practices among people who use drugs (PWUD) in New York City. Int J Drug Policy. 2018;60:82–88.
   PubMed Web of Science ®Google Scholar
• Reed M, Wagner KD, Tran NK, Brady KA, Shinefeld J, Roth A. Prevalence and correlates of carrying naloxone among a community-based sample of opioid-using people who inject drugs. Int J Drug Policy. 2019;73:32–35.
   PubMed Web of Science ®Google Scholar
• McDonald R, Parkin S, Eide D, et al. Rethinking ‘carriage’ of take-home naloxone. Int J Drug Policy. 2021;95:103253.
   PubMed Web of Science ®Google Scholar
• Joudrey PJ, Khan MR, Wang EA, et al. A conceptual model for understanding post-release opioid-related overdose risk. Addict Sci Clin Pract. 2019;14(1):17.
   PubMedGoogle Scholar
• Brinkley-Rubinstein L, Cloud DH, Davis C, et al. Addressing excess risk of overdose among recently incarcerated people in the USA: Harm reduction interventions in correctional settings. Int J Prison Health. 2017;13(1):25–31.
   PubMed Web of Science ®Google Scholar
• Huxley-Reicher Z, Maldjian L, Winkelstein E, et al. Witnessed overdoses and naloxone use among visitors to Rikers Island jails trained in overdose rescue. Addict Behav. 2018;86:73–78.
   PubMed Web of Science ®Google Scholar
• Wenger LD, Showalter D, Lambdin B, et al. Overdose education and naloxone distribution in the San Francisco county jail. J Correct Health Care. 2019;25(4):394–404.
   PubMed Web of Science ®Google Scholar
• Zucker H, Annucci AJ, Stancliff S, Catania H. Overdose prevention for prisoners in New York: a novel program and collaboration. Harm Reduct J. 2015;12:51.
   PubMed Web of Science ®Google Scholar
• Anthony-North V, Pope LG, Pottingher S, Sederbaum I. Corrections-based responses to the opioid epidemic: lessons from New York State’s overdose education and naloxone distribution program. 2018; https://www.vera.org/downloads/publications/corrections-responses-to-opioid-epidemic-new-york-state.pdf.
   Google Scholar
• Tobin K, Clyde C, Davey-Rothwell M, Latkin C. Awareness and access to naloxone necessary but not sufficient: examining gaps in the naloxone cascade. Int J Drug Policy. 2018;59:94–97.
   PubMed Web of Science ®Google Scholar
• Green TC, Donovan E, Klug B, et al. Revisiting pharmacy-based naloxone with pharmacists and naloxone consumers in 2 states: 2017 perspectives and evolving approaches. J Am Pharm Assoc. 2020;60(5):740–749.
   Google Scholar
• Donovan E, Case P, Bratberg JP, et al. Beliefs associated with pharmacy-based naloxone: a qualitative study of pharmacy-based naloxone purchasers and people at risk for opioid overdose. J Urban Health. 2019;96(3):367–378.
   PubMed Web of Science ®Google Scholar
• Green TC, Case P, Fiske H, et al. Perpetuating stigma or reducing risk? Perspectives from naloxone consumers and pharmacists on pharmacy-based naloxone in 2 states. J Am Pharm Assoc. 2017;57(2S):S19–S27.
   Google Scholar
• Krieter P, Chiang N, Gyaw S, et al. Pharmacokinetic properties and human use characteristics of an FDA-approved intranasal naloxone product for the treatment of opioid overdose. J Clin Pharmacol. 2016;56(10):1243–1253.
   PubMed Web of Science ®Google Scholar
• Rhodes B, Costenbader B, Wilson L, et al. Urban, individuals of color are impacted by fentanyl-contaminated heroin. Int J Drug Policy. 2019;73:1–6.
   PubMed Web of Science ®Google Scholar
• Stein MD, Kenney SR, Anderson BJ, Bailey GL. Perceptions about fentanyl-adulterated heroin and overdose risk reduction behaviors among persons seeking treatment for heroin use. J Subst Abuse Treat. 2019;104:144–147.
   PubMed Web of Science ®Google Scholar
• New York City Department of Health and Mental Hygiene. Health Department Launches Citywide Fentanyl Awareness Campaign. [Press Release]. 2019; https://www1.nyc.gov/site/doh/about/press/pr2019/health-department-launches-fentanyl-awareness-campaign.page.
   Google Scholar
• New York City Department of Health and Mental Hygiene. Increase in drug overdoses deaths and increased presence of fentanyl in New York City. Health Advisory 2016; https://www1.nyc.gov/assets/doh/downloads/pdf/han/advisory/fentanyl-overdose.pdf.
   Google Scholar
• New York City Department of Health and Mental Hygiene. Health department conducts public outreach to warn New Yorkers about the dangers of fentanyl. [Press release]. 2017; https://www1.nyc.gov/site/doh/about/press/pr2017/pr037-17.page.
   Google Scholar
• Olfson M, Wall M, Wang S, Crystal S, Blanco C. Risks of fatal opioid overdose during the first year following nonfatal overdose. Drug Alcohol Depend. 2018;190:112–119.
   PubMed Web of Science ®Google Scholar
• Lowder EM, Amlung J, Ray BR. Individual and county-level variation in outcomes following non-fatal opioid-involved overdose. J Epidemiol Community Health. 2020;74(4):369–376.
   PubMed Web of Science ®Google Scholar
• Karmali RN, Ray GT, Rubinstein AL, Sterling SA, Weisner CM, Campbell CI. The role of substance use disorders in experiencing a repeat opioid overdose, and substance use treatment patterns among patients with a non-fatal opioid overdose. Drug Alcohol Depend. 2020;209:107923.
   PubMed Web of Science ®Google Scholar
• Warfield S, Pollini R, Stokes CM, Bossarte R. Opioid-related outcomes in West Virginia, 2008–2016. Am J Public Health. 2019;109(2):303–305.
   PubMed Web of Science ®Google Scholar
• Welch AE, Jeffers A, Allen B, Paone D, Kunins HV. Relay: a peer-delivered emergency department-based response to nonfatal opioid overdose. Am J Public Health. 2019;109(10):1392–1395.
   PubMed Web of Science ®Google Scholar
• Burton G, McAuley A, Schofield J, Yeung A, Matheson C, Parkes T. A systematic review and meta-analysis of the prevalence of take-home naloxone (THN) ownership and carriage. Int J Drug Policy. 2021;96:103298.
   PubMed Web of Science ®Google Scholar
• Tse WC, Djordjevic F, Borja V, et al. Does naloxone provision lead to increased substance use? A systematic review to assess if there is evidence of a ‘moral hazard’ associated with naloxone supply. Int J Drug Policy. 2022;100:103513.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Influx of fentanyl-laced counterfeit pills and toxic fentanyl-related compounds further increases risk of fentanyl-related overdose and fatalities. Health Alert Network 2016; https://emergency.cdc.gov/han/han00395.asp.
   Google Scholar